13209-41-1
13209-41-1 structure
- Name: Vamorolone
- Chemical Name: 16α-Methyl-9,11-dehydro Prednisolone
- CAS Number: 13209-41-1
- Molecular Formula: C22H28O4
- Molecular Weight: 356.45500
- Catalog: Signaling Pathways GPCR/G Protein Glucocorticoid Receptor
- Create Date: 2017-07-01 10:58:18
- Modify Date: 2026-07-15 11:35:22
-
Vamorolone (VBP15) is a first-in-class, orally active dissociative steroidal anti-inflammatory drug and membrane-stabilizer. Vamorolone improves muscular dystrophy without side effects. Vamorolone shows potent NF-κB inhibition and substantially reduces hormonal effects[1][2].
| Name | 16α-Methyl-9,11-dehydro Prednisolone |
|---|---|
| Synonyms |
16Alpha-Methyl-9,11-dehydro Prednisolone
(16α)-17,21-Dihydroxy-16-Methylpregna-1,4,9-triene-3,20-dione Dexamethasone Imp E Cbamazine Impurity 22 17, 21-dihydroxy-16α-methylpregna- 1, 4, 9-triene-3,20-dione inhibit,rair,Mineralocorticoid Rector,VBP 15,Glucocorticoid Rector,NF-κB,inflammation,Duchenne,Inhibitor,membrane,dystrophy,Vamorolone,Nuclefactor-κB,Nuclefactor-kappaB,muscul,VBP-15,glucocorticoid 17,21-dihydroxy-16alpha-methylpregna-1,4,9-triene-3,20-dione Pregna-1,4,9-triene-3,20-dione, 17,21-dihydroxy-16-methyl-, (16α) (16alpha)-17,21-dihydroxy-16-methylpregna-1,4,9-triene-3,20-dione Dexamethasone Impurity 5(Dexamethasone Impurity E) Dexamethasone impurity E (8S,10S,13S,14S,16R,17R)-17-hydroxy Tobramycin and dexamethasone impurity C ((2R,3R,4aS,4bS,10aS,10bR,11S,12aS)-10b-fluoro-2,11-dihydroxy-3,10a,12a-trimethyl-1,8-dioxo-1,2,3,4,4a,4b,5,6,8,10a,10b,11,12,12a-tetradecahydrochrysen-2-yl)methyl dihydrogen phosphate VBP15 (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one Vamorolone, 10 mM in DMSO 16a-Methyl-9,11-dehydro prednisolone - Bio-X Dexamethasone Impurity L ethyl (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-cboxylate 17.alpha.,21-Dihydroxy-16.alpha.-methylpregna-1,4,9-triene-3,20-dione |
| Description | Vamorolone (VBP15) is a first-in-class, orally active dissociative steroidal anti-inflammatory drug and membrane-stabilizer. Vamorolone improves muscular dystrophy without side effects. Vamorolone shows potent NF-κB inhibition and substantially reduces hormonal effects[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Vamorolone (VBP15) inhibits TNFα-induced pro-inflammatory NF-κB signaling in C2C12 muscle cells at 1 nM or more. Vamorolone binds the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) with similar affinity[1]. Vamorolone (0.1, 1μM; 30 minutes) reduces production of IL1βand CCL5 inflammatory mediators in primary human macrophages[2]. Vamorolone is a first-in-class mineralocorticoid receptor (MR) antagonist/dissociative glucocorticoid receptor (GR) ligand[3]. |
| In Vivo | Vamorolone (5-30 mg/kg; cherry syrup) shows a superior side effect profile compared to pharmacological glucocorticoids in mdx mice[1]. Vamorolone (30 mg/kg; orally; daily for 20 days) reduces CNS Inflammation in murine experimental autoimmune encephalomyelitis[2]. Animal Model: C57BL/6 mice (experimental autoimmune encephalomyelitis)[2] Dosage: 30 mg/kg Administration: Orally; daily for 20 days (starting one day prior to MOG 33-55 peptide immunization and continuing) Result: Reduced CNS inflammation in murine experimental autoimmune encephalomyelitis. |
| References |
| Density | 1.24g/cm3 |
|---|---|
| Boiling Point | 548.3ºC at 760 mmHg |
| Molecular Formula | C22H28O4 |
| Molecular Weight | 356.45500 |
| Flash Point | 299.4ºC |
| Exact Mass | 356.19900 |
| PSA | 74.60000 |
| LogP | 2.75290 |
| Vapour Pressure | 2.63E-14mmHg at 25°C |
| Index of Refraction | 1.603 |
| Precursor 0 | |
|---|---|
| DownStream 1 | |
